Format

Send to

Choose Destination
J Infect Dis. 2017 Jun 15;215(12):1883-1887. doi: 10.1093/infdis/jix208.

Suppressor Cell-Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis.

Author information

1
Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
2
National Emerging Infectious Diseases Laboratories Institute, Boston University, Massachusetts.

Abstract

Host-directed therapies that augment host immune effector mechanisms may serve as important adjunctive therapies for tuberculosis treatment. We evaluated the activity of denileukin diftitox in an acute mouse model of tuberculosis (TB) infection and analyzed the cellular composition and bacterial burden in lungs and spleens. These in vivo studies show that denileukin diftitox potentiates standard TB treatment in the mouse model, an effect which may be due to depletion of T-regulatory and myeloid-derived suppressor cells during TB infection. Our results indicate that denileukin diftitox and other suppressor cell-depleting therapies may be useful adjunctive, host-directed therapies for TB.

KEYWORDS:

Denileukin diftitox recombinant fusion protein toxin; Host-directed therapy; Immunotherapy; Tuberculosis

PMID:
28863467
PMCID:
PMC5853937
DOI:
10.1093/infdis/jix208
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center